Verywell Health on MSN1d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant DepressionFact checked by Nick Blackmer The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, ...
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
ScienceAlert on MSN6d
FDA-Approved Nasal Spray For Depression Is First Of Its KindA ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...
Boing Boing on MSN5d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
They could also be cheaper, given that Spravato's US list price in the US is $590 to $885 for two doses. “Use of an extended-release oral dosage ketamine formulation may be advantageous compared ...
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback